eyeforpharma Philadelphia 2017: 6 in-depth conferences in one

eyeforpharma20 - 21 April 2017, Philadelphia, USA.
The democratization of healthcare is real, the healthcare delivery landscape is consolidating fast, and the patient is empowered and the customer in charge. Pharma needs to change and develop along with it. 6 in-depth commercial pharma conferences on the key issues of 2017 and beyond, the 6 eyeforpharma Philadelphia 2017 sessions will focus on:

Commercial Leadership

  • Commercial Leadership: Healthcare Leadership: How Pharma Embraces a New Customer Engagement Paradigm
  • Executive Commitment: Recognize Patient Centricity as a Journey: and Spearhead Cultural Change
  • Business Transformation: Your Company Needs to be Disrupted: Corporate Activism for Value Creation
  • Technology Partnerships: Tech meets Pharma: Life Science Partnerships from Bench to Bedside
  • Healthcare Challenges: Approaching the Caregiver Cliff: How Pharma Should Support the Supporters
  • The Implementation Panel: From Words to Action, How to Become a Pharma Intrapreneur

Patients as Partners

  • Patient advocacy 2.0: Manage ‘local customer engagement' from pre to post launch
  • The future of pharma-stakeholder collaboration: Lessons learnt from partnering in the rare disease field
  • Where rubber hits the road: Can patient centricity grow the bottom-line?
  • Case studies on understanding and acting on patient concern

Customer Experience

  • Is the new sales strategy to de-prioritize targets?
  • Customer experience is the key to commercial excellence
  • It's the experience that counts!
  • Look after your customer's journey from start to finish
  • Sales rep 2.0: The new portrait of a customer facing role

Commercial Model Innovation

  • A holistic commercial view: integrate your sales and marketing teams
  • Leverage untapped opportunities with patient-centric selling
  • Customer centricity is key. Are you doing enough?
  • The Modern Marketer: how to stay ahead in a competitive landscape

Pharma's Triple Aim

  • Strengthen the patient ecosystem - improve treatment adherence beyond physician support
  • How to innovate and differentiate your patient assistance solutions
  • Understand factors driving patients' treatment choices
  • Free your engagement from uncertainty around compliance

Digital Transformation

  • Maximize capabilities of your commercial teams with technology
  • Stay ahead of the curve: How digital integration takes your customer’s experience further
  • The power of integrating digital across all aspects of your organization
  • Leveraging Digital: Navigating digital trends and technologies to maximize positive outcomes for patients

Join the most forward thinking speakers from across North America including C-level, VPs and industry leaders from Shire, Otsuka, GSK, Novartis, Pfizer, Google, Sanofi, Takeda and many more. This is the ideal place to ensure your commercial strategy is prepared for 2017 and beyond.

World Pharma News readers can benefit from an exclusive discount - save $200 using our unique discount code WPN200 when you register online.

You can find full details of the meeting here.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...